Assessment of Interleukin-31 and Calprotectin in Immunocompromised Patients with Epstein-Barr Virus Infection
DOI:
https://doi.org/10.14500/aro.12398Keywords:
Calprotectin, Epstein-Barr Virus, Immunocompromised patient, Interleukin 31, SulaimaniAbstract
Epstein-Barr virus (EBV) is among the most concerning herpesviruses, despite its typically asymptomatic or mildly self-limiting infections. The virus’s carcinogenic features and its ability to modulate the immune system are critical. That is why more research is needed on the hidden aspects of the virus’s life cycle, especially its oncogenic role and post-transplant complications. The study aims to harness EBV’s unique characteristics to gain new insights into its pathogenesis. This study was designed to investigate immunological and inflammatory biomarkers among three immunocompromised groups compared with an immunocompetent group in Sulaimani City (n = 81), including identification of EBV seropositivity in association with interleukin (IL) 31, calprotectin, lactate dehydrogenase, total leukocytes, granulocytes, lymphocytes, and platelets. EBV viral capsid antigen (VCA) immunoglobulin (Ig)M seropositivity was 29%, 21%, 15%, and 0%, in the immunocompetent, renal transplant, bone marrow transplant (BMT), and hematological malignancy groups, respectively. In addition, VCA IgM was inversely correlated with age (r = −0.353, p = 0.001). Interestingly, a significant association between the EBV VCA IgM index and IL-31, and, consequently, calprotectin levels, was observed. Regarding hematological parameters, the study found no significant association with EBV seropositivity. In conclusion, EBV latent Ig was less commonly recorded in the hematology and BMT groups than in the kidney transplant and immunocompetent groups. The findings suggest a possible association between IL-31 and calprotectin levels with EBV seropositivity; however, additional mechanistic studies are required to determine causality or oncogenic relevance.
Downloads
References
Borgia, F., Custurone, P., Li Pomi, F.L., Cordiano, R., Alessandrello, C., and Gangemi, S., 2022. IL-31: State of the art for an inflammation-oriented interleukin. Molecular Sciences, 23, p.6507.
Chakravorty, S., Afzali, B., and Kazemian, M., 2022. EBV-associated diseases: Current therapeutics and emerging technologies. Frontiers in Immunology, 13, pp.1-29.
Dillon, S.R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S.R., Haugen, H.S., Maurer, M., Harder, B., Johnston, J., Bort, S., Mudri, S., Kuijper, J.L., Bukowski, T., Shea, P., Dong, D.L., Dasovich, M., Grant, F.J., Lockwood, L., Levin, S.D., LeCiel, C., Waggie, K., Day, H., Topouzis, S., Kramer, J., Kuestner, R., Chen, Z., Foster, D., Parrish-Novak, J., and Gross, J.A., 2004. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunology, 5(7), pp.752-760.
Elansary, M., El Haddad, H.E., Eldin, U.A.A.S., Hamdy, A., and Sherif, M.M., 2016. Seroprevalence and real-time PCR study of Epstein—Barr virus and the value of screening in pretransplant patients. The Egyptian Journal of Internal Medicine, 28(1), pp.9-15.
Ferretti, E., Tripodo, C., Pagnan, G., Guarnotta, C., Marimpietri, D., Corrias, M.V, Ribatti, D., Zupo, S., and Ravetti, J.L., 2015. The interleukin (IL) -31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia, 29(4), pp.958-967.
Fournier, B., and Latour, S., 2021. Immunity to EBV as revealed by immunedeficiencies. Current Opinion in Immunology, 72, pp.107-115. Frappier, L., 2021. Epstein-barr virus: Current questions and challenges. Tumour Virus Research, 12, p.200218.
Freuer, D., Linseisen, J., Waterboer, T., Pessler, F., Guzmán, C.A., Wawro, N., and different measures of obesity. PLoS One, 15(4), pp.1-16.
Jim, C., Fern, J., Aroca, M., Pellegrini, E., Contador, J., Hern, M., Valenzuela, F., and Fern, A., 2023. Association of periodontitis and atopic dermatitis with the levels of IL-13, IL-31, and TSLP in the gingival crevicular fluid. Molecular Sciences, 24, p.15592.
Jog, N.R., Chakravarty, E.F., Guthridge, J.M. and James, J.A., 2018. EpsteinBarr virus interleukin-10 suppresses the anti-inflammatory phenotype in human monocytes. Frontiers in Immunology, 9, pp.1-11.
Johnson, K.H., Webb, C.H., Schmeling, D.O., Brundage, R.C., and Balfour, H.H., 2016. Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: An intensive 6-month study. Clinical and Translational Immunology, 5(5), pp.e81-e85.
Kareem, K.A., Abd, A., and Sahib, A., 2025. Assessment of knowledge, attitude, practice, and related factors among a sample of patients with irritable bowel syndrome attending AlImamain AlKadhimain Medical City in 2023. Iraqi Journal of Community Medicine, 38, pp.1-8.
Keller, D., Mester, P., Räth, U., Krautbauer, S., Schmid, S., Greifenberg, V., Müller, M., Kunst, C., Buechler, C., and Pavel, V., 2024. Calprotectin, a promising serological biomarker for the early diagnosis of superinfections with multidrugresistant bacteria in patients with COVID-19. International Journal of Molecular Sciences, 25(17), p.9294.
Kimura, H., 2006. Pathogenesis of chronic active Epstein-Barr virus infection: Is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Reviews in Medical Virology, 16, pp.251-261.
Lehner, G.F., Klein, S.J., Zoller, H., Peer, A., Bellmann, R., and Joannidis, M., 2020. Correlation of interleukin-6 with Epstein–Barr virus levels in COVID-19. Critical Care, 24(1), pp.4-6.
Li, Yan, and Wang, Kun, 2024. Clinical analysis of 163 pediatric patients with infectious mononucleosis: A single-center retrospective analysis. Immunity, Inflammation and Disease, 12(9), p.e70020.
Lin, J., Chen, X., Wu, H., Chen, X., Hu, X., and Xu, J., 2021. Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection. American Journal of Translational Research, 13(11), pp.12797-12806.
Liu, S., Lei, Z., Li, J., Wang, L., Jia, R., Liu, Z., Jiang, C., Gao, Y., Liu, M., Kuang, L., Qian, Z., Zhou, D., Speck, S.H., and Liang, X., 2020. Interleukin 16 contributes to gammaherpesvirus pathogenesis by inhibiting viral reactivation. PLoS Pathogens, 16(7), pp.1-26.
Ming, D., Yu, X., Guo, R., Deng, Y., Li, J., Lin, C., Su, M., Lin, Z., and Su, Z., 2015. Elevated TGF-β1/IL-31 pathway is associated with the disease severity of Hepatitis B virus-related liver cirrhosis. Viral Immunology, 28(4), pp.209-216.
Muhealdeen, D.N., Shwan, A., Yaqo, R.T., Hassan, H.A., Muhammed, B.O., Ali, R.M., and Hughson, M.D., 2022. Epstein-Barr virus and Burkitt’s lymphoma. Associations in Iraqi Kurdistan and twenty-two countries assessed in the International Incidence of Childhood Cancer. Infectious Agents and Cancer, 17(1), pp.1-9.
Natalia, B.S., Gris, M.S., Baranov, A.A., Spirin, N.N., Artyuhov, A.S., Shakirova, K.M., and Nasonov, E.L., 2023. Clinical significance of cytokine counting in patients with multiple sclerosis and its relationship with herpes infection. Bulletin of Russian State Medical University, (4), pp.48-61.
Ning, S., 2011. Innate immune modulation in EBV infection. Herpesviridae, 2(1), p.1.
Ohashi, A., Uemura, Y., Yoshimori, M., Wada, N., Imadome, K.I., Yudo, K., Koyama, T., Shimizu, N., Nishio, M., and Arai, A., 2022. The plasma level of interleukin-1β can be a biomarker of angiopathy in systemic chronic active epstein–barr virus infection. Frontiers in Microbiology, 13, p.874998.
Orfali, R.L., and Aoki, V., 2023. Blockage of the IL-31 pathway as a potential Peters, A., and Meisinger, C., 2020. Seropositivity of selected chronic infections target therapy for atopic dermatitis. Pharmaceutics, 15, p.577.
Páez-Guillán, E.M., Campos-Franco, J., Alende, R., and Gonzalez-Quintela, A., 2023. Hematological abnormalities beyond lymphocytosis during infectious mononucleosis: Epstein-barr virus-induced thrombocytopenia. Mediterranean Journal of Hematology and Infectious Diseases, 15(1), pp.1-7.
Papageorgiou, D., Gogos, C., and Akinosoglou, K., 2024. Macrophage activation syndrome in viral sepsis. Viruses, 16, p.1004.
Rasmi, Y., Jalali, L., Khalid, S., Shokati, A., Tyagi, P., Ozturk, A., and Nasimfar, A., 2023. The effects of prolactin on the immune system, its relationship with the severity of COVID-19, and its potential immunomodulatory therapeutic effect. Cytokine, 169, p.156253.
Smatti, M.K., Yassine, H.M., AbuOdeh, R., AlMarawani, A., Taleb, S.A., Althani, A.A., and Nasrallah, G.K., 2017. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PLoS One, 12(12), pp.1-20.
Todorović, N., Ambrosio, M.R., and Amedei, A., 2024. Immune modulation by epstein–barr virus lytic cycle: Relevance and implication in oncogenesis. Pathogens, 13(10), p.876.
Toma, L., Dodot, M., Zgura, A., Bacalbasa, N., Silaghi, A., Simu, R., Isac, T., Stanciu, A.M., and Toma, L., 2022. Calprotectin in viral systemic infections — COVID - 19 versus hepatitis C virus. Clinical and Experimental Medicine, 22(2), pp.311-317.
Yamako, G., Chosa, E., Totoribe, K., Fukao, Y., and Deng, G., 2017. Quantification of the sit-to-stand movement for monitoring age-related motor deterioration using the Nintendo Wii Balance Board. PLoS One, 12(11), pp.1-12.
Yan, C., Xu, H., Rong, C., Cao, M., Miao, Z., and Zhou, H., 2022. IL-31 expression in HIV-infected patients with different routes of disease transmission. Medicine (United States), 101(25), p.E29509.
Yu, H., and Robertson, E.S., 2023. Epstein–barr virus history and pathogenesis. Viruses, 15, p.714.
Zhang, Y., Huang, C., Zhang, H., Duan, Z., Liu, Q., Li, J., Zong, Q., Wei, Y., Liu, F., Duan, W., Chen, L., Zhou, Q., and Wang, Q., 2023. Characteristics of immunological events in Epstein-Barr virus infection in children with infectious. Frontiers in Pediatrics, 11, p.1060053.
Zugmaier, G., Topp, M.S., Alekar, S., Viardot, A., Horst, H.A., Neumann, S., Stelljes, M., Bargou, R.C., Goebeler, M., Wessiepe, D., Degenhard, E., Gökbuget, N., and Klinger, M., 2014. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer Journal, 4(9), pp.4-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Awat R. Rahim-Majid, Muhammed Babakir-Mina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who choose to publish their work with Aro agree to the following terms:
-
Authors retain the copyright to their work and grant the journal the right of first publication. The work is simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-SA 4.0]. This license allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
-
Authors have the freedom to enter into separate agreements for the non-exclusive distribution of the journal's published version of the work. This includes options such as posting it to an institutional repository or publishing it in a book, as long as proper acknowledgement is given to its initial publication in this journal.
-
Authors are encouraged to share and post their work online, including in institutional repositories or on their personal websites, both prior to and during the submission process. This practice can lead to productive exchanges and increase the visibility and citation of the published work.
By agreeing to these terms, authors acknowledge the importance of open access and the benefits it brings to the scholarly community.
Accepted 2026-02-05
Published 2026-04-03
ARO Journal is a scientific, peer-reviewed, periodical, and diamond OAJ that has no APC or ASC.